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Rac1-Induced Connective Tissue
Growth Factor Regulates Connexin 43
and N-Cadherin Expression in Atrial Fibrillation
Oliver Adam, MD,* Daniel Lavall, MS,* Katharina Theobald, MS,* Mathias Hohl, PHD,*
Markus Grube, PHD,‡ Sabine Ameling, MS,§ Mark A. Sussman, PHD,
Stephan Rosenkranz, MD, PHD,¶ Heyo K. Kroemer, PHD,‡ Hans-Joachim Schäfers, MD,†
Michael Böhm, MD,* Ulrich Laufs, MD*
Homburg/Saar, Greifswald, and Köln, Germany; and San Diego, California
Objectives We studied the signal transduction of atrial structural remodeling that contributes to the pathogenesis of atrial
fibrillation (AF).
Background Fibrosis is a hallmark of arrhythmogenic structural remodeling, but the underlying molecular mechanisms are
incompletely understood.
Methods We performed transcriptional profiling of left atrial myocardium from patients with AF and sinus rhythm and applied
cultured primary cardiac cells and transgenic mice with overexpression of constitutively active V12Rac1 (RacET) in
which AF develops at old age to characterize mediators of the signal transduction of atrial remodeling.
Results Left atrial myocardium from patients with AF showed a marked up-regulation of connective tissue growth fac-
tor (CTGF) expression compared with sinus rhythm patients. This was associated with increased fibrosis, nico-
tinamide adenine dinucleotide phosphate oxidase, Rac1 and RhoA activity, up-regulation of N-cadherin and con-
nexin 43 (Cx43) expression, and increased angiotensin II tissue concentration. In neonatal rat cardiomyocytes
and fibroblasts, a specific small molecule inhibitor of Rac1 or simvastatin completely prevented the angiotensin
II–induced up-regulation of CTGF, Cx43, and N-cadherin expression. Transfection with small-inhibiting CTGF ribo-
nucleic acid blocked Cx43 and N-cadherin expression. RacET mice showed up-regulation of CTGF, Cx43, and
N-cadherin protein expression. Inhibition of Rac1 by oral statin treatment prevented these effects, identifying
Rac1 as a key regulator of CTGF in vivo.
Conclusions The data identify CTGF as an important mediator of atrial structural remodeling during AF. Angiotensin II activates
CTGF via activation of Rac1 and nicotinamide adenine dinucleotide phosphate oxidase, leading to up-regulation of
Cx43, N-cadherin, and interstitial fibrosis and therefore contributing to the signal transduction of atrial structural
remodeling. (J Am Coll Cardiol 2010;55:469–80) © 2010 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.08.064c
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atrial fibrillation (AF) is the most common arrhythmia.
tructural remodeling is an important substrate in AF (1).
tructural abnormalities including myocytic hypertrophy,
rom the *Klinik für Innere Medizin III, Kardiologie, Angiologie und Internistische
ntensivmedizin, and †Klinik für Thorax- und Herz-Gefässchirurgie, Univer-
itätsklinikum des Saarland, Homburg/Saar, Germany; Departments of ‡Pharmacol-
gy and §Functional Genomics, Ernst Moritz Arndt University, Greifswald, Ger-
any; SDSU Heart Institute and Department of Biology, San Diego State
niversity, San Diego, California; and the ¶Klinik III für Innere Medizin, Kardi-
logie, Pneumonologie, Angiologie und Internistische Intensivmedizin, Universität
u Köln, Köln, Germany. This study was supported by the Deutsche Forschungsge-
einschaft (Drs. Laufs and Böhm, Klinische Forschergruppe, KFO 196) and the
niversität des Saarlandes (HOMFOR, Dr. Adam). Drs. Adam and Lavall contrib-
ted equally to this work.p
Manuscript received March 10, 2009; revised manuscript received August 7, 2009,
ccepted August 10, 2009.entral loss of sarcomeres, and interstitial fibrosis result in
n increase of conduction heterogeneity, which facilitates
he maintenance of AF (2). The molecular mechanisms of
trial structural remodeling are incompletely understood.
See page 481
ecent evidence shows that increased atrial oxidative stress
ontributes to inducing and maintaining AF (1,3–5). The
eft atrium (LA) of patients with AF is characterized by
ncreased Rac1 and nicotinamide adenine dinucleotide
hosphate (NADPH) oxidase activity (4). The Rho guanosine
riphosphatase (GTPase) Rac1 regulates NADPH oxidase
ctivity and is critical for generating oxidative stress and
roducing cardiac left ventricular hypertrophy (6–8). No-
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3-methylglutaryl-coenzyme A
(HMG-CoA) reductase inhibi-
tors (statins) is able to inhibit
Rac1 activation by inhibiting its
geranylgeranylation and mem-
brane translocation (4,9,10). In
agreement with these observa-
tions, activation of the local renin-
angiotensin system in atrial tissue
has been found to play an impor-
tant role in atrial structural re-
modeling (11). Rac1 GTPase is a
mediator of angiotensin II in the
cardiovascular system (6,10).
Angiotensin II is known to cause
fibrosis in the kidney, liver, lung,
and myocardium (12). Fibrosis is
a hallmark of arrhythmogenic
structural remodeling (2,13).
There are few data regarding
structural remodeling and fibrosis
in human LA available. Therefore,
we performed transcriptional
profiling of LA myocardium
from patients with AF and sinus
rhythm (SR) and applied cul-
tured primary cardiac cells and
transgenic mice to characterize
mediators of the signal transduc-
tion of atrial remodeling.
ethods
ell isolation and culture. Cardiomyocytes and fibroblasts
ere isolated from neonatal Sprague-Dawley rat hearts
Charles River, Sulzfeld, Germany) (6). Purity of fibroblasts
as confirmed by vimentin staining. After 48 h in culture,
yocytes exhibited regular spontaneous contractions. Cells
ere used for experiments after 3 to 6 days of culture. The
9C2 embryonal rat (BD1X) heart-derived cells were
btained from American Type Culture Collection (Wesel,
ermany).
nimal studies. Mice with cardiac overexpression of con-
titutively active (V12) Rac1 under the control of the
-myosin heavy chain promoter (RacET, provided by Prof.
ark A. Sussman, SDSU Heart Institute and Department
f Biology, San Diego State University, San Diego, Cali-
ornia) and their friend virus B-type N strain wild-type
WT) controls (14) were fed with normal chow (ssniff,
oest, Germany) or normal chow supplemented with 0.4
g/d of commercially available rosuvastatin (Crestor, As-
raZeneca, Wedel, Germany) for 10 months. The study was
ot funded by the pharmaceutical industry. Overall, 44% of
Abbreviations
and Acronyms
AF  atrial fibrillation
CTGF  connective tissue
growth factor
Cx  connexin
ECG  electrocardiography
GTPase  guanosine
triphosphatase
HMG-CoA  3-hydroxy-3-
methylglutaryl-coenzyme A
LA  left atrium
NADPH  nicotinamide
adenine dinucleotide
phosphate
np-Cx43 
nonphosphorylated
connexin 43
qRT-PCR  quantitative
real-time polymerase chain
reaction
RacET  transgenic mice
with cardiac-specific
overexpression of a
constitutively active Rac1
RNA  ribonucleic acid
siRNA  small interfering
ribonucleic acid
SR  sinus rhythm
TGF  transforming growth
factor
WT  wild-typeacET showed AF compared with 20% of RacET plus statin treatment (p  0.05). None of the WT mice had AF
4). The Alb/transforming growth factor (TGF)-1
cys223,225ser) transgenic mice (TGF-1-TG, provided by
tephan Rosenkranz, Klinik III für Innere Medizin, Uni-
ersität Köln, Köln, Germany) were compared with their
57BL/6J WT controls (15). The study was approved by
he Animal Ethics Committee of the Universität des Saar-
andes and is in accord with the “Guide for the Care and
se of Laboratory Animals” published by the National
nstitutes of Health (NIH Pub. No. 85-23, revised 1996).
uman left atrial tissue. Tissue samples of the left atrial
ppendage of patients undergoing mitral valve surgery were
nalyzed in 5 patients with SR and in patients with
ermanent AF (documented by electrocardiography [ECG]
or 3 months; 5 patients per group, 4 males and 1 female,
espectively). There was no difference in atrial diameter, left
entricular function, medication, and age (SR 67  6 years
s. AF 63  8 years, p  NS) between both groups. The
atients did not receive drugs at least 12 h before surgery; no
atient was treated with a statin. The study of human
yocardial tissue was approved by the Ethics Committee of
he A¨rztekammer des Saarlandes (No. 131/00).
IBONUCLEIC ACID (RNA) ISOLATION. The RNA was iso-
ated following the manufacturer’s instructions for total
NA isolation from fibrous tissues (Qiagen, Hilden, Ger-
any). RNA concentration and quality were assessed using
NanoDrop ND-1000 (NanoDrop Technologies, Wil-
ington, Delaware) and an RNA 6000 Nano LabChip on
Bioanalyzer 2100 (Agilent Technologies, Santa Clara,
alifornia).
INEAR AMPLIFICATION AND ARRAY HYBRIDIZATION.
ranscriptional profiling of heart tissue of AF patients was
erformed with GeneChip-Human Genome-HGU 133-
lus 2.0 arrays (Affymetrix, Santa Clara, California). Two-
ound T7-RNA polymerase-mediated linear amplification
as performed starting with 50 ng RNA (2-cycle target
abeling protocol). Biotin-labeled amplified RNA size dis-
ribution was analyzed with an Agilent 2100 BioAnalyzer,
nd concentrations were determined using a NanoDrop
D-1000. After hybridization and washing, arrays were
canned using the GeneChip System Confocal Scanner
000 (Affymetrix).
EOXYRIBONUCLEIC ACID ARRAY DATA ANALYSIS. Af-
ymetrix HGU133-Plus 2.0 arrays query the expression of
4,675 probe sets. After analysis with Gene Chip Operating
oftware, expression raw data were transferred to Gene-
pring GX version 7.3.1. (Agilent Technologies) to perform
er-chip normalization for signals that were flagged in Gene
hip Operating software as present or marginal. Before
tatistical analysis, probe sets were filtered on the basis of
heir flags. Filtering was based on 80% of present/marginal
ignals in the Affymetrix data in at least 1 of the classes
ompared (control group vs. AF patients). The Cyber-T
tatistics program (University of California, Irvine, Califor-
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February 2, 2010:469–80 Connective Tissue Growth Factor in AFia) was used for the identification of genes differentially
xpressed between controls and AF patients. Application of
yber-T results in an average ratio and a p value for each
robe set. Expression data have been submitted to the
ational Center for Biotechnology Information gene-
xpression and hybridization-array data repository.
EASUREMENT OF ANGIOTENSIN II CONCENTRATION.
ngiotensin II concentration was determined by enzyme-
inked immunosorbent assay using Assay Max (Assay Pro,
t. Charles, Missouri).
ADPH OXIDASE ACTIVITY. NADPH oxidase activity was
easured by a lucigenin-enhanced chemiluminescence as-
ay, as described (6).
ESTERN BLOT ANALYSIS. Immunoblotting was performed
sing Anti-Rac1 (Rac1, Upstate, Billerica, Massachusetts,
lone 23A8), connexin 43 (Cx43 [Sigma, München, Ger-
any]), nonphosphorylated Cx43 (np-Cx43 [Invitrogen,
arlsruhe, Germany]), connexin 40 (Cx40 [Santa Cruz
iotechnology, Santa Cruz, California]), N-cadherin (Santa
ruz Biotechnology), TGF-1 (Santa Cruz Biotechnol-
gy), RhoA (Santa Cruz Biotechnology), and Tubulin
Santa Cruz Biotechnology), as described (6).
MALL INTERFERING RIBONUCLEIC ACID (SIRNA) TRANS-
ECTION. Transfection of H9C2 with CTGF siRNA
sc-39330, Santa Cruz Biotechnology) was performed ac-
ording to the manufacturer’s instructions; fluorescein con-
ugated scrambled siRNA (sc-36869) was used as control.
AC1 GST-PAK AND RHO GST-RHOTEKIN PULL-DOWN
SSAY. Pull-down assays were performed using agarose-
abeled PAK-1 fusion protein and Rhotekin fusion protein
both Upstate), as described (4).
EAL-TIME POLYMERASE CHAIN REACTION. Total RNA
as isolated from human left atrial myocardium using
eqGOLD TriFast (Peqlab Biotechnology GmbH, Erlan-
en, Germany) and transcribed using HighCap cDNA RT
it (Applied Biosystems, Darmstadt, Germany). Gene expres-
ion was then evaluated by quantitative real-time polymerase
hain reaction (qRT-PCR [StepOne Plus, Applied Biosys-
ems]) using Power SYBR Green (Applied Biosystems). Sig-
als were normalized to corresponding glyceraldehyde-3-
hosphate dehydrogenase controls. No template controls were
sed to monitor for contaminating amplifications. The Ct
as used for statistical analysis and 2Ct for data presenta-
ion. Oligonucleotide probes were as follows: human TGF-1
orward, GAC TGC GGA TCT CTG TGT CA; human
GF-1 reverse, GGG CAA AGG AAT AGT GCA GA;
uman CTGF forward, TTG GCA GGC TGA TTT CTA
G; human CTGF reverse, GGT GCA AAC ATG TAA
TT TTG G; human GAPDH forward, ATG ACA TCA
GA AGG TGG TG; human GAPDH reverse, CAT ACC
GG AAA TGA GCT TG; mouse Rac1 forward, AAC
TG CCT GCT CAT CAG TT; mouse Rac1 reverse, TTG
CC AGC TGT GTC CCA TA; mouse TGF-1 forward, wGC CCG AAG CGG ACT ACT AT; mouse TGF-1
everse, TCC ACA TGT TGC TCC ACA CT; mouse
TGF forward, AGC AGC TGG GAG AAC TGT GT;
ouse CTGF reverse, GCT GCT TTG GAA GGA CTC
C; mouse GAPDH forward, CCC TGC ATC CAC TGG
GC TGC; mouse GAPDH reverse, CAT TGA GAG
AA TGC CAG CCC.
ISTOLOGICAL ANALYSIS. Ten-m cryosections were
tained with 0.1% Sirius Red F3BA (Laboratory Imaging,
rague, Czech Republic). Lucia Measurement software,
ersion 4.6, was used for quantification of interstitial
brosis.
MMUNOFLUORESCENCE ANALYSIS. Indirect immunofluo-
escence was performed on paraffin-embedded sections of
he human LA applying monoclonal antibodies against
-sarcomeric actin (cardiomyocytes [Sigma-Aldrich,
ünchen, Germany]), CTGF (Santa Cruz Biotechnol-
gy), Cx43 (Sigma-Aldrich), and vimentin (fibroblasts
Dako Cytomation, Glostrup, Denmark]). Fluorescein
sothiocyanate- or tetramethyl rhodamine isothiocyanate-
onjugated (Dianova, Hamburg, Germany) anti-mouse im-
unoglobulin (Ig) M, anti-mouse IgG, and anti-goat IgG
ere used as secondary antibodies. Sections were counter-
tained with 4=,6 diamidino-2-phenylindole (DAPI [Cal-
iochem, Darmstadt, Germany]). Immunostaining with
uorescein isothiocyanate- or tetramethyl rhodamine
sothiocyanate-conjugated anti-mouse IgM, anti-mouse
gG, and anti-goat IgG as a negative control for nonspecific
taining was performed in parallel sections.
tatistical analysis. Band intensities were analyzed by
ensitometry. Mean, standard error of the mean (SEM),
nd statistical analysis were calculated by Sigma Stat soft-
are, version 2.0 (Systat Software, Erkrath, Germany).
npaired Student t tests and, in case of failing the normality
est, the Mann-Whitney rank-sum test for single compar-
son were performed. For all multiple comparisons, analysis
f variance followed by Newman-Keuls post-hoc analysis
or multiple comparisons was applied. Differences were
onsidered significant at p  0.05.
esults
ncreased CTGF expression and fibrosis in LA of
atients with AF. To identify mediators of the signal
ransduction of atrial remodeling during AF, expression
rofiling was performed by Affymetrix array. Tissue samples
f the LA appendage were analyzed in 5 patients with SR
nd 5 patients with permanent AF without differences in
trial diameter (54  2.2 mm vs. 55  1.8 mm, p  NS),
eft ventricular function (59  5.6% vs. 61  5.8%), and
edication. Screening of 25,000 genes by Affymetrix
rrays showed that a total of 426 genes displayed signifi-
antly altered expression patterns (p  0.01), and 122 genes
isplayed a more than twofold change in LA of patients
ith AF compared with SR. In addition to down-regulation
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Connective Tissue Growth Factor in AF February 2, 2010:469–80f genes associated with cardiac beta-adrenergic signaling
e.g., RYR2, PPP1R1A), elevated expression of genes
elated to remodeling (COL1A, COL1A2, COL3A1,
IMP1, CTGF) was observed (Fig. 1A). A literature search
dentified CTGF as a possible candidate in the pathogenesis
f tissue fibrosis. Up-regulation of CTGF was confirmed
y real-time polymerase chain reaction (RT-PCR [694 
42%, p  0.05 compared with SR]) (Fig. 1B) and
Huma
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40X
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Figure 1 Increased CTGF Expression and Fibrosis in LA of Patie
(A) Altered gene expression in patients with atrial fibrillation (AF). Ingenuity Pathwa
sion. Hierarchical clustering of left atrium (LA) tissue from patients with sinus rhyt
genes of eukaryotic cells. (B) Quantitative real-time polymerase chain reaction (qR
expression in LA of patients with SR or AF (n  5). *p  0.05. (C) Quantification
patients with SR or AF (n  5). *p  0.05. (D) Representative sirius red staining
SR or AF (n  5). *p  0.05. (E) Immunofluorescent imaging of CTGF protein (red
protein (red), the fibroblast marker vimentin (green), and cell nuclei (blue). (10- aestern blot analysis (205  28%, p  0.05) (Fig. 1C). gncreased expression of CTGF was associated with in-
reased interstitial fibrosis (175  25% of SR, p  0.05)
Fig. 1D). Immunofluorescent staining of LA from
atients with AF or SR showed a higher expression of
TGF in cardiomyocytes compared with cardiac fibro-
lasts (Figs. 1E and 1F).
ncreased angiotensin II tissue levels, N-cadherin, and
x43 expression in LA of patients with AF. To investi-
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February 2, 2010:469–80 Connective Tissue Growth Factor in AFA, we performed an enzyme-linked immunosorbent assay,
hich showed sevenfold increased tissue levels of angioten-
in II in AF compared with SR (28 3.4 pg/mg vs. 4 1.4
g/mg protein, p  0.001) (Fig. 2A). This observation is in
greement with our previous finding of a profound up-
egulation of Rac1 expression and of the superoxide-
roducing NADPH-oxidase in the LA of patients with
F (4). Because Rac1 plays a critical role in the activation
f the cytoskeleton, the expression of N-cadherin, a
ransmembrane regulator of the actin cytoskeleton and
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Figure 2 Increased Angiotensin II Tissue Levels, N-Cad, and Cx
(A) Quantification of angiotensin II tissue levels, detected by enzyme-linked immun
of (B) N-cadherin (N-cad), (C) connexin 43 (Cx43), (D) connexin 40 (Cx40), and (E
*p  0.05 and **p  0.001 versus patients with SR. (F) Representative Western
localization in relation to -sarcomeric actin (green) and cell nuclei (blue) (10-, 40
tions as in Figure 1.alcium-dependent adhesion, was investigated (16). destern blot analysis showed a 2-fold up-regulation of
-cadherin (196  54% of SR, p  0.04) (Fig. 2B) in the
A of patients with AF. Adherens junction formation is
prerequisite for gap junction assembly (16,17). Both
x43 and Cx40 have been shown to represent important
ap junctions in the myocardium and are involved in the
athogenesis of AF (18). Western blot analysis showed
p-regulation of Cx43 (188  18%, p  0.001) (Fig.
C). In contrast, Cx40 expression was not altered (77 
0% of SR, p  NS) (Fig. 2D). The Cx43 function
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xpression of np-Cx43 was markedly down-regulated,
ndicating an elevation of phosphorylation in AF (33 
% of SR; p  0.05) (Figs. 2E and 2F). Immunostaining
or Cx43 showed a lateralization and disseminated ex-
ression of Cx43 in atrial myocytes of AF patients
ompared with a localization at the longitudinal cell
ermini in SR patients (Fig. 2G).
TGF regulates N-cadherin and Cx43 expression in
eonatal cardiomyocytes and fibroblasts. To test whether
x43 or N-cadherin is regulated by CTGF, cultured neo-
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Quantification and representative Western blots showing the effects of treatment w
(B) N-cad, and (C) Rac1 protein expression in neonatal rat cardiomyocytes; and o
blasts related to tubulin (n  5). *p  0.05 and **p  0.001 versus control (C).
interfering ribonucleic acid (siRNA) transfection (si-CTGF [sc-CTGF  scrambled rib
siRNA-mediated knockdown on (H) Cx43 and (I) N-cad expression (n  4). *p  0atal rat cardiomyocytes were treated with recombinant
TGF (1 ng/ml for 1 h), which resulted in a moderate but
ignificant up-regulation of Cx43 protein expression (133
% of vehicle treatment, p  0.001) (Fig. 3A) and an
p-regulation of N-cadherin to 181 17% (p 0.05) (Fig.
B). In contrast, expression of Rac1 GTPase was not
ffected by CTGF treatment (Fig. 3C). Because cardio-
yocytes only account for 45% of the atrial myocardium
y volume, CTGF treatments were repeated in fibroblasts,
hich exhibited very similar effects (Figs. 3D to 3F). To
larify the causal role of CTGF in this signal transduction,
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iRNA-mediated knockdown of CTGF (Fig. 3G) pre-
ented angiotensin-mediated up-regulation of Cx43 (196
5%, p  0.05) and N-cadherin (236  57%, p  0.05)
Figs. 3G to 3I), whereas basal Cx43 expression (83  37%
f control, p  NS) and basal N-cadherin expression (94 
4% of control, p  NS) were unaffected by CTGF-siRNA
reatment.
ac1-dependent CTGF expression in neonatal cardio-
yocytes and fibroblasts. To test whether the observed
ctivation of Rac1 GTPase in AF atria plays a causal role
or the observed effects, neonatal rat cardiomyocytes and
broblasts were stimulated with angiotensin II (1 M for
h) after pre-incubation with or without the Rac1-
pecific small molecule inhibitor NSC23766 (100 nM,
1 h). The NSC prevents Rac1 activation by inhibition of
he Rac-specific guanine nucleotide exchange factors
rioN and Tiam1 without affecting Cdc42 or RhoA
ctivation. Western blot analysis showed up-regulation of
TGF expression after stimulation with angiotensin II to
38  45%, which was completely prevented by pre-
ncubation with the small molecule inhibitor (53  9%,
 0.05) (Fig. 4A). Angiotensin II increased N-cadherin and
x43 expression to 234% and 254% of control, respectively
p  0.05) (Figs. 4B to 4D), which was completely
revented by NSC23766. These data show that Rac1
TPase mediates the angiotensin II–induced regulation of
-cadherin and Cx43.
In addition to cholesterol lowering, inhibition of
MG-CoA reductase by statins leads to inhibition of
soprenoid synthesis. Statins have been shown to reduce
ac1 activity in cardiomyocytes by blocking Rac1 iso-
renylation (6,8 –10). Pre-treatment of cardiomyocytes
ith simvastatin (1 M for 21 h) completely prevented
he angiotensin II–induced up-regulation of CTGF (p 
.05) (Figs. 4E and 4F).
These experiments were repeated in fibroblasts. Simi-
arly to cardiomyocytes, Western blot analysis showed a
ignificant up-regulation of CTGF expression after stim-
lation with angiotensin II that was completely prevented
y pre-incubation with the Rac1 small molecule inhibitor
194  27% angiotensin II, p  0.05; 79  24%
ngiotensin II  NSC23766, p  0.05) (Fig. 5A).
reatment with angiotensin II increased N-cadherin and
x43 expression to 138% and 180%, respectively (p 
.05) (Figs. 5B to 5D), which was prevented by
SC23766, showing that Rac1 GTPase mediates the
ngiotensin II–induced regulation of CTGF, N-cadherin,
nd Cx43 in cardiac fibroblasts similar to the effects ob-
erved in myocytes.
eduction of Rac1 activity by statin decreases CTGF,
-cadherin, and Cx43 expression in vivo. Because of the
imitation of our cell culture model using ventricular cardio-
yocytes and fibroblasts and to further characterize the
nteraction of Rac1, CTGF, and structural remodeling
uring AF in vivo, we studied transgenic mice with 4ardiac overexpression of constitutively active (V12) Rac1
nder the control of the -myosin heavy chain promoter
RacET) that spontaneously develop AF at high age (4).
acET shows a marked 	30-fold up-regulation of Rac1
ctivity compared with WT (4). Statin treatment (rosu-
astatin 0.4 mg/day orally for 10 months; n  10 per
roup) reduced Rac1 activity, superoxide release by
ADPH oxidase, and the risk of AF (4). Histological
nalysis showed that the marked increase of Rac1 activity
n RacET was associated with a significant increase of
trial interstitial fibrosis (324  60% vs. WT) (Fig. 6A).
tatin treatment showed a nonsignificant trend toward
educing atrial interstitial fibrosis in RacET (RacET 243 
Figure 4 Rac1-Dependent CTGF
Expression in Neonatal Cardiomyocytes
Effects of treatment with Ang II (1 M, 3 h) and the specific Rac1 small mole-
cule inhibitor NSC23766 (NSC [100 nM, 21 h]) on the expression of (A) CTGF,
(B) N-cad, and (C) Cx43 in relation to tubulin in neonatal rat cardiomyocytes.
(D) Representative Western blots (n  5). *p  0.05 versus C. (E, F) Western
blot analysis of the effects of treatment with Ang II (10 M, 3 h) and simvasta-
tin (1 M, 24 h) on CTGF in neonatal cardiac myocytes (n  5). *p  0.05
versus C. Abbreviations as in Figures 2 and 3.0% of WT, p  0.06) (Fig. 6A). Interestingly, RacET
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8% vs. WT; p  0.001) (Fig. 6B), which was observed in
acET in AF as well as in SR. Statin treatment reduced
TGF expression to 235  46% compared with WT
ontrols. Similarly, N-cadherin (752 54%, p 0.05) (Fig.
C) and Cx43 (317  68%, p  0.05) (Fig. 6D) were
arkedly increased in RacET compared with WT. Statin
reatment reduced the Rac1-induced N-cadherin expression
o 384  21% (p  0.05) (Fig. 6C) and reduced Cx43
xpression below WT levels (84 8%, p 0.05) (Fig. 6D).
imilar to the human left atria, Cx40 expression was not
hanged in RacET compared with WT (Fig. 6E).
GF-1 activates Rac1 and CTGF. The transcriptional
rofiling (Fig. 1A) shows that latent TGF-1 binding
rotein 1, the activator of latent form of TGF-1, is
p-regulated in the LA of AF patients, which was
onfirmed by qRT-PCR (386  84% vs. SR, p  0.05)
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Figure 5 Rac1-Dependent CTGF
Expression in Neonatal Cardiac Fibroblasts
Quantification of (A) CTGF, (B) N-cad, and (C) Cx43 protein expression in rela-
tion to tubulin in neonatal rat cardiac fibroblasts after stimulation with Ang II
(1 M, 3 h) and the Rac1 small molecule inhibitor NSC23766 (NSC [100 nM,
21 h]). (D) Representative Western blots (n  5). *p  0.05 versus C. Abbre-
viations as in Figures 2 and 3.Fig. 7A). TGF- is the canonical mediator of CTGFnduction (19). Expression of TGF-1 was unchanged in
acET mice (80  14% vs. WT, p  NS) (Fig. 7B).
ice overexpressing TGF-1 were characterized by in-
reased CTGF expression (353  15% vs. WT, p  0.05)
Fig. 7C) and Rac1 expression (214  32% vs. WT, p 
.05) (Fig. 7D). These data suggest that TGF-1 is
pstream of Rac1 and CTGF in this signal transduction.
ross-talk between Rac1 and RhoA GTPases. Western
nalysis and Rhotekin-GST pull-down assay revealed a
arked up-regulation of RhoA protein expression as well
s activity in the LA of patients with AF (189 
8% vs. SR and 388  75% vs. SR, respectively; p  0.05)
Figs. 7E and 7F). RacET showed increased RhoA activity,
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Figure 6 Reduction of Rac1 Activity by Statin
Decreases CTGF, N-Cad, and Cx43 Expression In Vivo
Transgenic mice with cardiac overexpression of constitutively active (V12)
Rac1 under the control of the -myosin heavy chain (MHC) promoter (RacET)
and RacET10 treated with rosuvastatin 0.4 mg/d orally for 10 months
(RacETStatin) compared with corresponding wild-type (WT) controls. (A) Quan-
tification of atrial interstitial fibrosis by sirius red staining (n  10). *p  0.05
versus WT. Quantification of (B) CTGF, (C) N-cad, (D) Cx43, and (E) Cx40 pro-
tein expression related to tubulin. (F) Representative Western blots (n  10
per group). *p  0.05 versus WT. **p  0.001 versus WT. #p  0.05 versus
RacET. Abbreviations as in Figures 2 and 3.
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T, p  0.05) (Fig. 7G). Inhibition of Rac1 with
SC23766 (100 nM for 21 h) in neonatal cardiomyocytes
educed angiotensin II–induced RhoA activity (180  9%
s. 127  7% of control) (Fig. 7H). Treatment with the
nhibitor of Rho-associated protein kinases Y27632 (10 M
or 21 h) reduced Rac1-activity, to a smaller extent, how-
ver, compared with the inhibition of angiotensin II–
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Figure 7 TGF-1 Activates Rac1 and CTGF/Cross-Talk Betwee
qRT-PCR of transforming growth factor (TGF)-1 messenger ribonucleic acid (mRNA
mice compared with wild-type (WT) controls (n  5; p  NS). qRT-PCR of (C) CTGF
mice (TGF-1-TG) compared with WT (n  5). *p  0.05. (E) Quantification and re
fication and representative Rhotekin pull-down of RhoA activity in left atrium of pat
pull-down of RhoA activity in (G) RacET and RacET10 treated with rosuvastatin 0.4
0.05. (H) Representative Rhotekin pull-down of RhoA activity and in neonatal rat c
Rac1 small molecule inhibitor NSC23766 (NSC [100 nM, 21 h]). (I) Representativ
(1 M, 3 h) and the selective inhibitor of Rho-associated protein kinases Y 27632nduced RhoA activity by NSC (Fig. 7I). Taken together, ahe data support a cross-talk between the small GTPases
ac1 and RhoA (20) in the LA myocardium and during the
athogenesis of AF.
iscussion
he data identify CTGF as an important mediator during
F in humans (Fig. 8). The study shows that angiotensin II
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D) Rac1 mRNA expression in TGF-1 (cys223,225ser) overexpressing transgenic
tative Western blot of RhoA protein expression related to tubulin, and (F) quanti-
ith SR or AF (n  5). *p  0.05. Quantification and representative Rhotekin
orally for 10 months (RacETstatin) compared with WT controls (n  5). *p 
yocytes after treatment with angiotensin II (Ang II [1 M, 3 h]) and the specific
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Connective Tissue Growth Factor in AF February 2, 2010:469–80TPase and NADPH oxidase activity, which contribute to
he signal transduction of structural remodeling in left
uman atria, leading to up-regulation of Cx43, N-cadherin,
nd interstitial fibrosis.
Structural remodeling and contractile dysfunction of
he LA play a fundamental role in the pathology of AF
2). Reactive oxygen species produced upon angiotensin
I–induced activation of the Rac1-dependent NADPH
xidase contribute to atrial remodeling (4,6,8,21,22).
ere, Affymetrix analysis revealed that the atria of
atients with AF are characterized by up-regulation of
TGF expression. CTGF is a member of the Cyr61
cysteine rich protein 61), CTGF (connective tissue growth
actor), and NOV (nephroblastoma overexpressed gene)
amily of cysteine-rich secreted proteins that participate in
he proliferation, migration, adhesion, and differentiation of
broblasts. CTGF plays a role in the extracellular matrix
emodeling that occurs during physiological processes such
s embryogenesis, implantation, and wound healing (23,24).
ncreased expression of CTGF has been found in human
therosclerotic and myocardial lesions as well as in the aorta
f angiotensin II–infused rats (19,25,26). Our data show
hat the LA myocardium of AF patients is characterized
y increased angiotensin II tissue concentrations, up-
egulation of CTGF, and interstitial fibrosis compared with
A from SR patients of similar size.
Experiments with neonatal cardiomyocytes and fibro-
lasts confirmed the up-regulation of CTGF by angiotensin
I, an effect that is completely inhibited by a Rac1 specific
mall molecule inhibitor. Similarly, statin treatment that
nhibits Rac1 activity is able to prevent the angiotensin
I–induced CTGF expression. To further assess the role of
yocardial Rac1 for CTGF expression, transgenic mice,
Ang II
O2
-
NAD(P)H
Oxidase
Statint ti
N-cadherin- istructural
remodeling
atrial fibrillation
tr t r l
r li
tri l fi rill ti Connexin 43i
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Figure 8 Rac1-Induced CTGF Regulates
Connexin 43 and N-Cadherin Expression in AF
Activation of connective tissue growth factor (CTGF) via Rac1, leading to
up-regulation of connexin 43, N-cadherin, and interstitial fibrosis, contributing
to the signal transduction of atrial structural remodeling. Ang II  angiotensin
II; NAD(P)H  nicotinamide adenine dinucleotide phosphate oxidase; TGF 
transforming growth factor.verexpressing Rac1 with highly increased NADPH oxidase Cctivity, were studied and show a marked elevation of
TGF. Importantly, AF develops in these animals at older
ge (4), but increased CTGF expression is observed in SR
efore the AF develops, suggesting a contribution of CTGF
o the development of AF. Interestingly, in human lens
pithelial cell line B3, reactive oxygen species increase
TGF mRNA expression, probably via activation of janus-
inase-2/-3 (27). Taken together, these data suggest that
ac1 induces CTGF expression via NADPH oxidase–
enerated reactive oxygen species.
The myocardial effects of angiotensin II are not limited to
ardiomyocytes but are also present in fibroblasts. Indeed,
ngiotensin II has been shown to induce extracellular matrix
rotein synthesis and secretion in cardiac fibroblast. Car-
iomyocytes probably do not directly synthesize collagen
ut influence structural remodeling through interactions
ith neighboring fibroblasts (28). In addition to profibrotic
ctions, mechanical stretch of fibroblasts may modulate
yocyte electrical activity by interfering with the intercel-
ular transfer of electrical signals.
Gap junctions formed by connexins maintain intercel-
ular ion conduction as well as metabolic coupling.
lterations in ventricular expression and function of the
ajor cardiac connexin, Cx43, correlate with proarrhyth-
ic conduction slowing and connexin disorganization by
edistribution to lateral cell borders, and altered phos-
horylation of connexins is associated with fibrosis
29 –31). Adherens junctions are responsible for mechan-
cal coupling between myocytes (for review, see Boengler
t al. [18]). In cardiomyocytes, N-cadherin is 1 of the
ajor transmembrane components of adherins junctions.
he assembly of N-cadherin precedes the accumulation
f Cx43 in cultured adult myocytes (17), and gap junction
ormation is perturbed in N-cadherin-null myocytes (32).
hese findings suggest that cadherin transduces signals
hat control the localization of Cx43. The Rac1 GTPase
as been observed to be affected by structural changes of
ell to cell junctions (33–35). We therefore investigated
he expression of N-cadherin and Cx43 in our 3 models.
he LA of patients with AF is characterized by up-
egulation of N-cadherin as well as by Cx43 expression in
ardiomyocytes and fibroblasts that is prevented by NSC
3766 or siRNA-mediated knockdown of CTGF. Im-
ortantly, stimulation with recombinant CTGF leads to
ncreased expression of N-cadherin and Cx43. Growth
actors have been shown to alter N-cadherin expression
uring changes of cellular phenotypes, for example,
uring epithelial-mesenchymal transition of PMC42-LA
ells treated with endothelial growth factor; however, the
etailed mechanisms of the CTGF-induced changes have
o be addressed in further studies (36). Taken together,
he data identify CTGF as a mediator of angiotensin
I–induced regulation of junction proteins during atrial
brillation.
Angiotensin II is not the only upstream mediator of
TGF; the expression profiling and confirmation assays
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February 2, 2010:469–80 Connective Tissue Growth Factor in AFhow up-regulation of TGF-1 in the LA of patients
ith AF. Mice overexpressing TGF-1 are characterized
y increased CTGF and up-regulation of Rac1. In
ontrast, RacET mice showed no significant alteration of
GF-1 expression. Further cell culture experiments
howed that stimulation with TGF-1 triggers GTP
inding to Rac1 within minutes (37), suggesting that
GF-1 activates Rac1 and CTGF in this signal trans-
uction. These data support the importance of CTGF in
he signaling of atrial fibrosis. Further studies are needed
o clarify the mechanism of TGF-1 regulation in
atients with AF and the interaction of TGF-1 with
ac1 (37).
onclusions
n addition to Rac1, the LA of AF patients is characterized
y up-regulation of RhoA expression and activity. In agree-
ent with the literature, our experiments show cross-talk
etween Rac1 and RhoA GTPases (20). In addition to
ontributing to the Rac1 signaling, RhoA may exert Rac1-
ndependent effects during AF that have to be studied
urther. Both Rac1 and RhoA are inhibited by HMG-CoA
eductase inhibitors (statins), which reduce isoprenylation-
ependent small G-protein function (6,8,10). Indeed, statin
reatment reduced the expression of CTGF and of Cx43
nd N-cadherin in cell culture, as well as in the RacET
ice. These data are in agreement with the reduction of AF
n the RacET mice by statin treatment (4) and with
merging clinical evidence suggesting preventive effects of
tatins for patients at risk for AF (5). Therefore, we believe
hat further characterization of the signal transduction of
he pathogenesis of AF has the potential to identify addi-
ional targets for the prevention of AF.
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